GlassScriptPhysician profile
Kristin E Mullally
NPI 1508014028
$9,773.59
in general payments reported to CMS, 2019-2025
40 companies · $3,218 in 2025
The $3,218 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,336 · 2022: $1,014 · 2023: $1,755 · 2024: $2,451 · 2025: $3,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,424.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,520.43 | 2021-2025 | |
| Pfizer INC. | $1,004.41 | 2021-2025 | |
| Amgen INC. | $835.18 | 2021-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $760.54 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $692.46 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $571.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $488.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $448.29 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $356.35 | 2022-2025 | |
| Amarin Pharma, INC. | $322.39 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $319.28 | 2021-2023 | Austedo Xr, Ajovy, Ajovy |
| Lilly USA, LLC | $288.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $196.36 | 2021 | |
| Exact Sciences Corporation | $192.14 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $167.74 | 2022-2024 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.24 | 2022-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $160.67 | 2021-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $117.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $113.07 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $112.22 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $104.81 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $103.01 | 2021-2024 | Spravato, Xarelto |
| Corium, LLC | $94.53 | 2023-2025 | Azstarys |
| Ucb, INC. | $93.59 | 2024 | Nayzilam, Rystiggo |
| Sanofi-Aventis U.S. LLC | $68.15 | 2024-2025 | |
| Astellas Pharma US INC | $66.71 | 2023-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $54.82 | 2022-2025 | Verquvo, Lagevrio, Belsomra |
| Eisai INC. | $53.00 | 2021-2025 | |
| Esperion Therapeutics, INC. | $50.55 | 2024-2025 | Nexletol |
| Lundbeck LLC | $39.69 | 2023-2025 | Rexulti |
| Ibsa Pharma INC. | $35.35 | 2021-2024 | Licart, Tirosint |
| Boston Scientific Corporation | $34.69 | 2025 | Watchman |
| Arbor Pharmaceuticals, INC. | $30.79 | 2021 | |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $18.72 | 2021 | |
| Shield Therapeutics INC | $16.07 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.67 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $15.63 | 2025 | |
| Collegium Pharmaceutical, INC. | $13.20 | 2023 | Xtampza |
| Kowa Pharmaceuticals America, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Mullally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.